The development of an effective vaccine has been hindered by the enormous diversity of
human immunodeficiency virus‐1 (HIV‐1) and its ability to escape a myriad of host immune …

Soon after HIV was discovered as the cause of AIDS in 1983–1984, there was an
expectation that a preventive vaccine would be rapidly developed. In trying to achieve that …

The envelope protein of human immunodeficiency virus (HIV) is synthesized as a
polyprotein(gp160) and cleaved intracellularly to a gp120-gp41 heterodimer. In this study …

Virus-specific cytotoxic T lymphocytes (CTL) which kill virus-infected cells are thought to be a
major host defence against viral infections1–11. Here we report the existence of human …

We describe functional simplified T cell and Fc receptor chimeras that are capable of
directing CD8+ cytotoxic T lymphocytes (CTLs) to specifically recognize and lyse cells …

LIVE-VIRUS vaccines have been well recognized as a cause of severe complications when
inadvertently administered to recipients with impaired immunologic function. 1 The acquired …

Formation of syncytia, with progression to cell death, is a characteristic feature of in vitro
cultures of susceptible cells infected with human T-lymphotropic virus type …

The envelope (env) glycoprotein of human immunodeficiency virus type 1 (HIV-1) consists of
two noncovalently associated subunits, gp120 and gp41, that are formed gradient …

In a randomised phase I trial of a recombinant vaccinia virus vaccine expressing the gp160
envelope gene of the human immunodeficiency virus (HIVAC-1e) 35 healthy, HIV …

The structures of the molecular clones employed in this study are presented in Figure 1. The
plasmid pHXl32gpt contains a biologically active HTLV-III proviral clone inserted in the …